This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.

Cicero AFG, F.F. (2021). Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. MEDICINA, 57(1), 1-18 [10.3390/medicina57010058].

Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update

Cicero AFG
Primo
Conceptualization
;
Borghi C.
Ultimo
Supervision
2021

Abstract

This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.
2021
Cicero AFG, F.F. (2021). Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. MEDICINA, 57(1), 1-18 [10.3390/medicina57010058].
Cicero AFG, Fogacci F, Kuwabara M, Borghi C.
File in questo prodotto:
File Dimensione Formato  
Cicero AFG_Therapeutic strategies_Medicina2021.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 383.24 kB
Formato Adobe PDF
383.24 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/826447
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 44
social impact